Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity

Samer O. Abdul-Hay, Amy L. Lane, Thomas Caulfield, Clémence Claussin, Juliette Bertrand, Amandine Masson, Shakeel Choudhry, Abdul H. Fauq, Guhlam M. Maharvi, Malcolm A. Leissring

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Insulin-degrading enzyme (IDE) is an atypical zinc-metallopeptidase that degrades insulin and the amyloid ß-protein and is strongly implicated in the pathogenesis of diabetes and Alzheimer's disease. We recently developed the first effective inhibitors of IDE, peptide hydroxamates that, while highly potent and selective, are relatively large (MW > 740) and difficult to synthesize. We present here a facile synthetic route that yields enantiomerically pure derivatives comparable in potency to the parent compounds. Through the generation of truncated variants, we identified a compound with significantly reduced size (MW = 455.5) that nonetheless retains good potency (ki = 78 ± 11 nM) and selectivity for IDE. Notably, the potency of these inhibitors was found to vary as much as 60-fold in a substrate-specific manner, an unexpected finding for active site-directed inhibitors. Collectively, our findings demonstrate that potent, small-molecule IDE inhibitors can be developed that, in certain instances, can be highly substrate selective.

Original languageEnglish (US)
Pages (from-to)2246-2255
Number of pages10
JournalJournal of Medicinal Chemistry
Volume56
Issue number6
DOIs
StatePublished - Mar 28 2013

Fingerprint

Insulysin
Peptides
Amyloidogenic Proteins
Metalloproteases
Enzyme Inhibitors
Zinc
Catalytic Domain
Alzheimer Disease
Insulin

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity. / Abdul-Hay, Samer O.; Lane, Amy L.; Caulfield, Thomas; Claussin, Clémence; Bertrand, Juliette; Masson, Amandine; Choudhry, Shakeel; Fauq, Abdul H.; Maharvi, Guhlam M.; Leissring, Malcolm A.

In: Journal of Medicinal Chemistry, Vol. 56, No. 6, 28.03.2013, p. 2246-2255.

Research output: Contribution to journalArticle

Abdul-Hay, SO, Lane, AL, Caulfield, T, Claussin, C, Bertrand, J, Masson, A, Choudhry, S, Fauq, AH, Maharvi, GM & Leissring, MA 2013, 'Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity', Journal of Medicinal Chemistry, vol. 56, no. 6, pp. 2246-2255. https://doi.org/10.1021/jm301280p
Abdul-Hay, Samer O. ; Lane, Amy L. ; Caulfield, Thomas ; Claussin, Clémence ; Bertrand, Juliette ; Masson, Amandine ; Choudhry, Shakeel ; Fauq, Abdul H. ; Maharvi, Guhlam M. ; Leissring, Malcolm A. / Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity. In: Journal of Medicinal Chemistry. 2013 ; Vol. 56, No. 6. pp. 2246-2255.
@article{805194bef4454c3b80f8f6185351debb,
title = "Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity",
abstract = "Insulin-degrading enzyme (IDE) is an atypical zinc-metallopeptidase that degrades insulin and the amyloid {\ss}-protein and is strongly implicated in the pathogenesis of diabetes and Alzheimer's disease. We recently developed the first effective inhibitors of IDE, peptide hydroxamates that, while highly potent and selective, are relatively large (MW > 740) and difficult to synthesize. We present here a facile synthetic route that yields enantiomerically pure derivatives comparable in potency to the parent compounds. Through the generation of truncated variants, we identified a compound with significantly reduced size (MW = 455.5) that nonetheless retains good potency (ki = 78 ± 11 nM) and selectivity for IDE. Notably, the potency of these inhibitors was found to vary as much as 60-fold in a substrate-specific manner, an unexpected finding for active site-directed inhibitors. Collectively, our findings demonstrate that potent, small-molecule IDE inhibitors can be developed that, in certain instances, can be highly substrate selective.",
author = "Abdul-Hay, {Samer O.} and Lane, {Amy L.} and Thomas Caulfield and Cl{\'e}mence Claussin and Juliette Bertrand and Amandine Masson and Shakeel Choudhry and Fauq, {Abdul H.} and Maharvi, {Guhlam M.} and Leissring, {Malcolm A.}",
year = "2013",
month = "3",
day = "28",
doi = "10.1021/jm301280p",
language = "English (US)",
volume = "56",
pages = "2246--2255",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "6",

}

TY - JOUR

T1 - Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity

AU - Abdul-Hay, Samer O.

AU - Lane, Amy L.

AU - Caulfield, Thomas

AU - Claussin, Clémence

AU - Bertrand, Juliette

AU - Masson, Amandine

AU - Choudhry, Shakeel

AU - Fauq, Abdul H.

AU - Maharvi, Guhlam M.

AU - Leissring, Malcolm A.

PY - 2013/3/28

Y1 - 2013/3/28

N2 - Insulin-degrading enzyme (IDE) is an atypical zinc-metallopeptidase that degrades insulin and the amyloid ß-protein and is strongly implicated in the pathogenesis of diabetes and Alzheimer's disease. We recently developed the first effective inhibitors of IDE, peptide hydroxamates that, while highly potent and selective, are relatively large (MW > 740) and difficult to synthesize. We present here a facile synthetic route that yields enantiomerically pure derivatives comparable in potency to the parent compounds. Through the generation of truncated variants, we identified a compound with significantly reduced size (MW = 455.5) that nonetheless retains good potency (ki = 78 ± 11 nM) and selectivity for IDE. Notably, the potency of these inhibitors was found to vary as much as 60-fold in a substrate-specific manner, an unexpected finding for active site-directed inhibitors. Collectively, our findings demonstrate that potent, small-molecule IDE inhibitors can be developed that, in certain instances, can be highly substrate selective.

AB - Insulin-degrading enzyme (IDE) is an atypical zinc-metallopeptidase that degrades insulin and the amyloid ß-protein and is strongly implicated in the pathogenesis of diabetes and Alzheimer's disease. We recently developed the first effective inhibitors of IDE, peptide hydroxamates that, while highly potent and selective, are relatively large (MW > 740) and difficult to synthesize. We present here a facile synthetic route that yields enantiomerically pure derivatives comparable in potency to the parent compounds. Through the generation of truncated variants, we identified a compound with significantly reduced size (MW = 455.5) that nonetheless retains good potency (ki = 78 ± 11 nM) and selectivity for IDE. Notably, the potency of these inhibitors was found to vary as much as 60-fold in a substrate-specific manner, an unexpected finding for active site-directed inhibitors. Collectively, our findings demonstrate that potent, small-molecule IDE inhibitors can be developed that, in certain instances, can be highly substrate selective.

UR - http://www.scopus.com/inward/record.url?scp=84875750447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875750447&partnerID=8YFLogxK

U2 - 10.1021/jm301280p

DO - 10.1021/jm301280p

M3 - Article

VL - 56

SP - 2246

EP - 2255

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 6

ER -